[go: up one dir, main page]

AU2001269766A1 - Compositions and methods for the therapy and diagnosis of colon cancer - Google Patents

Compositions and methods for the therapy and diagnosis of colon cancer

Info

Publication number
AU2001269766A1
AU2001269766A1 AU2001269766A AU6976601A AU2001269766A1 AU 2001269766 A1 AU2001269766 A1 AU 2001269766A1 AU 2001269766 A AU2001269766 A AU 2001269766A AU 6976601 A AU6976601 A AU 6976601A AU 2001269766 A1 AU2001269766 A1 AU 2001269766A1
Authority
AU
Australia
Prior art keywords
diagnosis
therapy
compositions
methods
colon cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269766A
Inventor
Jonathan D. Clapper
William T. Hepler
Yuqiu Jiang
Heather Secrist
Aijun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2001269766A1 publication Critical patent/AU2001269766A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001269766A 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer Abandoned AU2001269766A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21082100P 2000-06-09 2000-06-09
US60/210,821 2000-06-09
US25657100P 2000-12-18 2000-12-18
US60/256,571 2000-12-18
US29024001P 2001-05-10 2001-05-10
US60/290,240 2001-05-10
PCT/US2001/018577 WO2001096390A2 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer

Publications (1)

Publication Number Publication Date
AU2001269766A1 true AU2001269766A1 (en) 2001-12-24

Family

ID=27395561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269766A Abandoned AU2001269766A1 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer

Country Status (6)

Country Link
US (1) US20020040127A1 (en)
EP (1) EP1287029A2 (en)
JP (1) JP2004512023A (en)
AU (1) AU2001269766A1 (en)
CA (1) CA2411278A1 (en)
WO (1) WO2001096390A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
PL366626A1 (en) * 2000-03-29 2005-02-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP3712393B2 (en) 2000-10-20 2005-11-02 エーザイ株式会社 Nitrogen-containing aromatic ring derivatives
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002092001A2 (en) * 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2002329000A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
EP1482034A4 (en) * 2002-06-06 2005-09-21 Yamanouchi Pharma Co Ltd Novel oxidase
EP1520046A2 (en) * 2002-06-27 2005-04-06 Aarhus University Disease risk estimating method using sequence polymorphisms in a specific region of chromosome 19
ES2291750T3 (en) 2002-12-20 2008-03-01 F. Hoffmann-La Roche Ag USE OF NICOTINAMIDE-N-METHYLTRANSPHERASE AS A COLORRECTAL CANCER MARKER.
WO2004080462A1 (en) * 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kit KINASE INHIBITOR
EP1607404A4 (en) * 2003-03-14 2008-01-23 Taisho Pharmaceutical Co Ltd MONOCLONAL ANTIBODY AND HYBRIDOMA PRODUCING THE SAME
WO2005021739A1 (en) * 2003-09-01 2005-03-10 Kureha Corporation ANTIBODY AGAINST Nox1 POLYPEPTIDE, METHOD OF DIAGNOSING CANCER WITH THE USE OF Nox1 GENE AND METHOD OF SCREENING CANCER GROWTH INHIBITOR
BRPI0414446A (en) * 2003-09-18 2006-11-14 Genmab As methods for screening for a therapeutic agent, for suppressing the polynucleotide sequence, for treating a non-steroidal cancer, for screening for binding of an agent specifically to a polynucleotide, and for determining whether a patient is at risk for developing or having a non-steroidal cancer, pharmaceutical composition, uses of a therapeutic agent, an antisense molecule or a cell that expresses and / or contains the antisense molecule, at least one of the immunogenic membrane proteins, fragments, derivatives or homologues thereof or from a cell containing and / or expressing at least one of the immunogenic membrane proteins or fragments, derivatives or homologues thereof and an agent or antibody, agent, and kit for identifying a patient at risk of developing or have non-steroidal cancer
WO2005044788A1 (en) * 2003-11-11 2005-05-19 Eisai Co., Ltd. Urea derivative and process for producing the same
US7927313B2 (en) * 2004-05-27 2011-04-19 Baxter International Inc. Medical device configuration based on recognition of identification information
EP1797881B1 (en) * 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
WO2007015569A1 (en) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CN101277720A (en) * 2005-09-01 2008-10-01 卫材R&D管理有限公司 Process for producing pharmaceutical composition with improved disintegrability
JPWO2007052849A1 (en) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination use of angiogenesis inhibitor and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Anti-tumor agent for multiple myeloma
CN104706637A (en) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008026748A1 (en) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JP5319306B2 (en) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition for treatment of undifferentiated gastric cancer
ES2608583T3 (en) * 2007-07-27 2017-04-12 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-tumor vaccine
UA103751C2 (en) * 2007-07-27 2013-11-25 Имматикс Биотекнолоджис Гмбх Immunogenic peptide for immunotherapy
JP5638244B2 (en) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of angiogenesis inhibitors and antitumor platinum complexes
US20100324087A1 (en) * 2008-01-29 2010-12-23 Eisai R&D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
KR101051435B1 (en) * 2008-10-22 2011-07-22 한국생명공학연구원 Colorectal cancer diagnostic kit using colorectal cancer-related markers and colorectal cancer diagnostic method using the same
CN102470133B (en) 2009-08-19 2013-08-28 卫材R&D管理有限公司 Pharmaceutical composition containing quinoline derivative
KR101677790B1 (en) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2841809T3 (en) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarkers to predict and evaluate the degree of response of subjects with thyroid and kidney cancer to lenvatinib compounds
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd Amorphous form of quinoline derivative, and method for producing same
RU2658601C2 (en) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
BR112017002827B1 (en) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME
CN107427505A (en) 2015-02-25 2017-12-01 卫材R&D管理有限公司 Method for suppressing the bitter taste of quinoline derivatives
KR20250020678A (en) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
RU2718048C2 (en) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Antitumour therapeutic agent
WO2017175253A1 (en) * 2016-04-04 2017-10-12 国立研究開発法人医薬基盤・健康・栄養研究所 Exosome-targeted dna vaccine
CN110072528B (en) 2017-02-08 2022-04-26 卫材R&D管理有限公司 Pharmaceutical composition for treating tumor
CN110831597A (en) 2017-05-16 2020-02-21 卫材R&D管理有限公司 Treatment of hepatocellular carcinoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118760C (en) * 1993-04-21 2004-06-22 William Jeffrey Allard Diagnosis and monitoring of colon cancer patients by measurement of nca 50/90 in blood
ATE317451T1 (en) * 1998-05-21 2006-02-15 Diadexus Inc METHOD FOR DIAGNOSIS, DETECTION, AND CLASSIFICATION OF COLON CANCER
AU773187B2 (en) * 1998-06-01 2004-05-20 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
ES2279647T3 (en) * 1998-11-10 2007-08-16 Emory University MITOGENIC REGULATORS.
EP1265582A2 (en) * 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001049716A2 (en) * 1999-12-30 2001-07-12 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001055323A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001252945A1 (en) * 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
EP1287028A2 (en) * 2000-06-09 2003-03-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2416285A1 (en) * 2000-07-17 2002-01-24 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020136728A1 (en) * 2000-08-03 2002-09-26 King Gordon E Compositions and methods for the therapy and diagnosis of colon cancer

Also Published As

Publication number Publication date
WO2001096390A3 (en) 2002-12-27
CA2411278A1 (en) 2001-12-20
WO2001096390A2 (en) 2001-12-20
US20020040127A1 (en) 2002-04-04
JP2004512023A (en) 2004-04-22
EP1287029A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001266790A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002253899A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer